Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10764676rdf:typepubmed:Citationlld:pubmed
pubmed-article:10764676lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0023821lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0074129lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0008387lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0085202lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0243144lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:10764676lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:10764676pubmed:issue4lld:pubmed
pubmed-article:10764676pubmed:dateCreated2000-4-27lld:pubmed
pubmed-article:10764676pubmed:abstractTextApolipoproteins of high density lipoprotein (HDL) and especially apolipoprotein (apo)AI and apoAII have been demonstrated as binding directly to the class B type I scavenger receptor (SR-BI), the HDL receptor that mediates selective cholesteryl ester uptake. However, the functional relevance of the binding capacity of each apolipoprotein is still unknown. The human adrenal cell line, NCI-H295R, spontaneously expresses a high level of SR-BI, the major apoAI binding protein in these cells. As previously described for murine SR-BI, free apoAI, palmitoyl-oleoyl-phosphatidylcholine (POPC)-AI, and HDL are good ligands for human SR-BI. In vitro displacement of apoAI by apoAII in HDLs or in Lp AI purified from HDL by immunoaffinity enhances their ability to compete with POPC-AI to bind to SR-BI and also enhances their direct binding capacity. The next step was to determine whether the higher affinity of apoAII for SR-BI correlated with the specific uptake of cholesteryl esters from these HDLs. Free apoAII and, to a lesser extent, free apoAI that were added to the cell medium during uptake experiments inhibited the specific uptake of [(3)H]cholesteryl esters from HDL, indicating that binding sites on cells were the same as cholesteryl ester uptake sites. In direct experiments, the uptake of [(3)H]cholesteryl esters from apoAII-enriched HDL was highly reduced compared with the uptake from native HDL. These results demonstrate that in the human adrenal cell line expressing SR-BI as the major HDL binding protein, efficient apoAII binding has an inhibitory effect on the delivery of cholesteryl esters to cells.lld:pubmed
pubmed-article:10764676pubmed:languageenglld:pubmed
pubmed-article:10764676pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:citationSubsetIMlld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10764676pubmed:statusMEDLINElld:pubmed
pubmed-article:10764676pubmed:monthAprlld:pubmed
pubmed-article:10764676pubmed:issn1079-5642lld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:ClavelAAlld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:FruchartJ CJClld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:CastroGGlld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:BriandOOlld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:CopinCClld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:PilonAAlld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:LestavelSSlld:pubmed
pubmed-article:10764676pubmed:authorpubmed-author:MajdZZlld:pubmed
pubmed-article:10764676pubmed:issnTypePrintlld:pubmed
pubmed-article:10764676pubmed:volume20lld:pubmed
pubmed-article:10764676pubmed:ownerNLMlld:pubmed
pubmed-article:10764676pubmed:authorsCompleteYlld:pubmed
pubmed-article:10764676pubmed:pagination1074-81lld:pubmed
pubmed-article:10764676pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:meshHeadingpubmed-meshheading:10764676...lld:pubmed
pubmed-article:10764676pubmed:year2000lld:pubmed
pubmed-article:10764676pubmed:articleTitleApolipoprotein AII enrichment of HDL enhances their affinity for class B type I scavenger receptor but inhibits specific cholesteryl ester uptake.lld:pubmed
pubmed-article:10764676pubmed:affiliationINSERM U325, Institut Pasteur de Lille et Université Lille 2, Lille, France.lld:pubmed
pubmed-article:10764676pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:335entrezgene:pubmedpubmed-article:10764676lld:entrezgene
entrez-gene:336entrezgene:pubmedpubmed-article:10764676lld:entrezgene
entrez-gene:949entrezgene:pubmedpubmed-article:10764676lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10764676lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:10764676lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10764676lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10764676lld:pubmed